Barcode
2025-11-07

$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ $Amgen(AMGN)$ 🚨📰💉 LILLY & NOVO JUST SHOOK UP HEALTHCARE 💉📰🚨

The White House has reportedly STRUCK A DEAL with $LLY and $NVO to SLASH prices on Wegovy and Zepbound, the two GLP-1 titans redefining modern medicine.

👉 Direct-to-consumer access could fall to $149/month (down from $300–$500)

👉 Medicare & Medicaid coverage incoming, marking a monumental policy shift

👉 Together, $LLY and $NVO raked in $18B+ in GLP-1 sales last quarter alone

I’m watching how margin compression trades off against explosive unit expansion, and how both navigate production scaling under policy-driven demand surges.

⚡This isn’t just healthcare reform, it’s a market rerating event loading

👉❓If GLP-1s become as affordable as aspirin, what happens to the entire pharma landscape?

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerWire @TigerPM @TigerStars @Daily_Discussion 

# 💰Stocks to watch today?(23 Jan）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

  • Top
  • Latest
  • PetS
    ·2025-11-07
    TOP
    📈🗞️ What an inflection point for big pharma. This agreement would not just scale patient access but accelerate competitive innovation. I’d like to see if $PFE or $AZN follow suit to stay relevant in the GLP-1 expansion race.
    Reply
    Report
  • Tui Jude
    ·2025-11-07
    🚀📰 The potential for $LLY and $NVO to dominate a subsidised market is unreal. The accessibility shift could push GLP-1 uptake beyond obesity into cardiovascular and metabolic therapy. Watching how this filters through margins and forward guidance will be 🔑
    Reply
    Report
  • Kiwi Tigress
    ·2025-11-07
    this is actually crazy. one policy shift and suddenly $LLY and $NVO feel like they’re playing a whole different game. I’m not even surprised though, they’ve basically turned weight loss into an economy of its own. kinda wild watching $AMGN just sneak up into the convo too
    Reply
    Report
  • Hen Solo
    ·2025-11-07
    💊我对这项政策如何标志着预防性治疗经济学的政治接受印象深刻。它也可能引发关于生物仿制药的平行立法。如果$AMGN利用其研发深度，它可能会抓住这一医疗保健转变的次要受益者。
    Reply
    Report